Pituitary adenylate cyclase activating polypeptide in the retina: Focus on the retinoprotective effects

T. Atlasz, K. Szabadfi, P. Kiss, B. Racz, F. Gallyas, A. Tamas, V. Gaal, Zs Marton, R. Gabriel, D. Reglodi

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects against different neuronal injuries, such as traumatic brain and spinal cord injury, models of neurodegenerative diseases, and cerebral ischemia. PACAP and its receptors are present in the retina. In this study, we summarize the current knowledge on retinal PACAP with focus on the retinoprotective effects. Results of histological, immunohistochemical, and molecular biological analysis are reviewed. In vitro, PACAP shows protection against glutamate, thapsigargin, anisomycin, and anoxia. In vivo, the protective effects of intravitreal PACAP treatment have been shown in the following models of retinal degeneration in rats: excitotoxic injury induced by glutamate and kainate, ischemic injury, degeneration caused by UV-A light, optic nerve transection, and streptozotocin-induced diabetic retinopathy. Studying the molecular mechanism has revealed that PACAP acts by activating antiapoptotic and inhibiting proapoptotic signaling pathways in the retina in vivo. These studies strongly suggest that PACAP is an excellent candidate retinoprotective agent that could be a potential therapeutic substance in various retinal diseases.

Original languageEnglish
Pages (from-to)128-139
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume1200
DOIs
Publication statusPublished - Jul 2010

    Fingerprint

Keywords

  • PACAP
  • neuropeptide
  • retinal injury
  • retinoprotection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this